Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.
Toledo RA, Garralda E, Mitsi M, Pons T, Monsech J, Vega E, Otero Á, Albarran MI, Baños N, Durán Y, Bonilla V, Sarno F, Camacho-Artacho M, Sanchez-Perez T, Perea S, Álvarez R, De Martino A, Lietha D, Blanco-Aparicio C, Cubillo A, Domínguez O, Martínez-Torrecuadrada JL, Hidalgo M. Toledo RA, et al. Among authors: alvarez r. Clin Cancer Res. 2018 Aug 1;24(15):3550-3559. doi: 10.1158/1078-0432.CCR-18-0103. Epub 2018 Mar 27. Clin Cancer Res. 2018. PMID: 29588308
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Toledo RA, Cubillo A, Vega E, Garralda E, Alvarez R, de la Varga LU, Pascual JR, Sánchez G, Sarno F, Prieto SH, Perea S, Lopéz-Casas PP, López-Ríos F, Hidalgo M. Toledo RA, et al. Among authors: alvarez r. Oncotarget. 2017 May 23;8(21):35289-35300. doi: 10.18632/oncotarget.13311. Oncotarget. 2017. PMID: 27852040 Free PMC article. Clinical Trial.
Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'.
Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M. Alvarez R, et al. Br J Cancer. 2014 Oct 14;111(8):1677-8. doi: 10.1038/bjc.2014.129. Epub 2014 Mar 18. Br J Cancer. 2014. PMID: 24642623 Free PMC article. No abstract available.
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.
Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M. Alvarez R, et al. Br J Cancer. 2013 Aug 20;109(4):926-33. doi: 10.1038/bjc.2013.415. Epub 2013 Aug 1. Br J Cancer. 2013. PMID: 23907428 Free PMC article.
Management of hyperbilirubinaemia in pancreatic cancer patients.
Álvarez R, Carrato A, Adeva J, Alés I, Prados S, Valladares M, Macarulla T, Muñoz A, Hidalgo M. Álvarez R, et al. Eur J Cancer. 2018 May;94:26-36. doi: 10.1016/j.ejca.2018.01.078. Epub 2018 Mar 20. Eur J Cancer. 2018. PMID: 29505968 Review.
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects.
Bazan-Peregrino M, Garcia-Carbonero R, Laquente B, Álvarez R, Mato-Berciano A, Gimenez-Alejandre M, Morgado S, Rodríguez-García A, Maliandi MV, Riesco MC, Moreno R, Ginestà MM, Perez-Carreras M, Gornals JB, Prados S, Perea S, Capella G, Alemany R, Salazar R, Blasi E, Blasco C, Cascallo M, Hidalgo M. Bazan-Peregrino M, et al. Among authors: alvarez r. J Immunother Cancer. 2021 Nov;9(11):e003254. doi: 10.1136/jitc-2021-003254. J Immunother Cancer. 2021. PMID: 35149591 Free PMC article. Clinical Trial.
2,123 results